Felix Hausch | Drug Discovery | Best Researcher Award

Posted on by ScienceFather

Prof. Felix Hausch | Drug Discovery | Best Researcher AwardĀ 

Professor, Technische UniversitƤt Darmstadt, Germany

Professor Prof. Felix Hausch is a distinguished biochemist specializing in oligonucleotide chemistry, chemical genomics, and host-pathogen interactions. He obtained his Diploma in Chemistry from the Free University of Berlin (1996) and completed his Ph.D. in Biochemistry in 2000 under the mentorship of Prof. Dr. A. JƤschke. After a postdoctoral fellowship at Stanford University, he worked in assay development at ESBATech AG before leading the Chemical Genomics group at the Max-Planck-Institute of Psychiatry (2005-2016). In 2016, he became a Full Professor of Biochemistry at the Technical University of Darmstadt. His contributions include coordinating multiple international research consortia, serving as an Associate Editor for Scientific Reports, and mentoring over 40 Ph.D. students and postdoctoral researchers. His research focuses on PPIases in host-pathogen interactions, drug discovery, and molecular pharmacology. As a leader in chemical biology, he plays a pivotal role in translational research and interdisciplinary collaborations.

Professional ProfileĀ 

EducationĀ 

Diploma in Chemistry (1996) ā€“ Free University of Berlin, Germany Doctorate in Biochemistry (2000) ā€“ Free University of Berlin, under Prof. Dr. A. JƤschke, focusing on oligonucleotide chemistry. Postdoctoral Research (2000-2002) ā€“ Stanford University, Institute of Chemical Engineering, under Prof. Chaitan Khosla, studying biochemical engineering.Habilitation in Organic Chemistry & Biochemistry (2015) ā€“ Ludwig-Maximilians-University (LMU), Munich. Full Professor of Biochemistry (2016-Present) ā€“ Technical University Darmstadt, specializing in chemical biology, medicinal chemistry, and host-pathogen interactions.

ExperienceĀ 

Research Assistant (1996-2000) ā€“ Free University of Berlin, Biochemistry. Postdoctoral Fellow (2000-2002) ā€“ Stanford University, specializing in chemical engineering and enzyme function. Scientist in Assay Development (2002-2004) ā€“ ESBATech AG, Zurich, focusing on biochemical assay development. Group Leader, Chemical Genomics (2005-2016) ā€“ Max-Planck-Institute of Psychiatry, Munich, leading chemical biology and drug discovery projects.

Awards & Honors šŸ†

Coordinator of MSCA Doctoral Network MC4DD (2024-2028) ā€“ EU-funded research program. Speaker, LOEWE-Schwerpunkt TRABITA (2020-2024) ā€“ Advancing chemical biology and drug discovery. Vice Director, Clemens-Schƶpf-Institute (2019-Present) ā€“ Leading biochemical research collaborations. Chair of GDCh Local Section (2019-2022) ā€“ Strengthening chemical research networks.Coordinator of BMBF Consortia PROCERA, iMIP, SIAM-APH & 51TaValP, ProxiTRAPS, FamoGLUES ā€“ Leading international drug discovery projects

Research Focus šŸ”¬

Chemical Biology & Drug Discovery ā€“ Developing novel small-molecule inhibitors for protein targets. Ā Host-Pathogen Interactions ā€“ Investigating PPIases and their role in bacterial and viral infections.Ā Molecular Pharmacology ā€“ Understanding enzyme mechanisms and drug-target interactions. Ā Peptidyl-Prolyl Cis/Trans Isomerases (PPIases) ā€“ Studying their function in cellular signaling and infection control. Translational Research ā€“ Bridging the gap between fundamental biochemistry and clinical applications. Chemical Genomics ā€“ Using biochemical assays and structural biology to develop targeted therapies.

Conclusion

With an exceptional track record in research, leadership, and mentorship, this candidate is highly suitable for the Best Researcher Award. Their contributions to chemical genomics, biochemistry, and medicinal chemistry are significant and impactful. Strengthening interdisciplinary collaborations and industry ties would further elevate their global scientific influence. šŸš€

Publications Top Noted

šŸ“Œ Structural Insights into PPIase-Mediated Protein Folding and Drug Targeting
šŸ“Œ Development of Small-Molecule Inhibitors for Host-Pathogen Interactions
šŸ“Œ Chemical Genomics Strategies for Understanding Protein Function
šŸ“Œ Biochemical Assay Development for High-Throughput Drug Screening
šŸ“Œ Molecular Mechanisms of Enzyme Catalysis in Drug Discovery
šŸ“Œ Role of Peptidyl-Prolyl Cis/Trans Isomerases in Cellular Regulation
šŸ“Œ Host-Pathogen Interactions: The Role of PPIases in Bacterial Infections
šŸ“Œ Advances in Chemical Biology: New Strategies for Molecular Targeting
šŸ“Œ Enzyme Modulation for Therapeutic Applications in Infectious Diseases
šŸ“Œ Drug Discovery Approaches Using Chemical Genomics Techniques

Morteza Alizadeh | Tissue Engineering | Best Researcher Award

Posted on by ScienceFather

Assist Prof Dr. Morteza Alizadeh | Tissue Engineering | Best Researcher Award

University Professor atĀ Department of Tissue Engineering and Biomaterials, School of Advanced Medical Sciences and Technologies, Hamadan University of Medical Sciences, Hamadan, Iran

Morteza Alizadeh has significantly contributed to the field of tissue engineering and regenerative medicine with a series of impactful publications. His work includes innovative research on cell-loaded hydrogels with bioactive glass nanoparticles for skin substitutes, which demonstrates impressive antibacterial properties and immune responses (Bioengineering & Translational Medicine, 2022, 44 citations). Alizadeh has also explored advanced diagnostic and drug release systems using microneedle arrays for breast cancer therapy (Journal of Controlled Release, 2021, 44 citations). His research on 3D-printed PCL-based scaffolds for bone tissue engineering and the evaluation of vacuum washing methods for decellularized bovine pericardium highlights his expertise in developing novel materials and techniques for tissue repair (Frontiers in Bioengineering and Biotechnology, 2023, 35 citations; Heliyon, 2019, 41 citations). These contributions, among others, underscore Alizadehā€™s role as a leading researcher in tissue engineering and regenerative medicine.

Professional Profiles:
Education Background

Morteza Alizadeh’s educational journey reflects a solid foundation in biomedical sciences. He earned his Ph.D. in Tissue Engineering from Shahrekord University of Medical Sciences, following an MSc in Histology and a BSc in Laboratory Sciences. His diverse academic background, including veterinary studies, underscores his comprehensive understanding of biological sciences and engineering.

Professional Experience

His roles as an Assistant Professor, Technical Supervisor, and Production Supervisor illustrate a diverse professional background that integrates academic, research, and industrial perspectives. This multifaceted experience is valuable for bridging theoretical knowledge with practical applications.

Research Interests and Experience

Alizadeh’s research interests are extensive, covering critical areas such as skin, bone, nerve, and vascular tissue engineering. His work on bio-materials, scaffold fabrication techniques, and 3D bioprinting aligns with cutting-edge advancements in regenerative medicine. His current and past research projects, like the development of polymer neural conduits and the investigation of chicken pericardium for tissue engineering, demonstrate a practical application of his knowledge.

Honors and Activities

Alizadeh’s achievements, such as ranking first in his Ph.D. entrance exam and receiving appreciation from the Cellular and Molecular Research Center, reflect his excellence and recognition in his field. His involvement in professional societies and development of research facilities further underscores his commitment to advancing tissue engineering.

Publications Top noted
  • Title: Cell loaded hydrogel containing Agā€doped bioactive glassā€“ceramic nanoparticles as skin substitute: Antibacterial properties, immune response, and scarless cutaneous wound ā€¦
    Year: 2022
    Citations: 44
    Publication: Bioengineering & Translational Medicine
    Emoji: šŸ§¬šŸ’§šŸ¦ 
  • Title: Diagnostic and drug release systems based on microneedle arrays in breast cancer therapy
    Year: 2021
    Citations: 44
    Publication: Journal of Controlled Release
    Emoji: šŸŽÆšŸ©ŗšŸ’‰
  • Title: Evaluation of vacuum washing in the removal of SDS from decellularized bovine pericardium: method and device description
    Year: 2019
    Citations: 41
    Publication: Heliyon
    Emoji: šŸ§ŖšŸ”¬šŸ§¼
  • Title: Recent advances on 3D-printed PCL-based composite scaffolds for bone tissue engineering
    Year: 2023
    Citations: 35
    Publication: Frontiers in Bioengineering and Biotechnology
    Emoji: šŸ¦“šŸ–ØļøšŸ”§
  • Title: Criteria, challenges, and opportunities for acellularized allogeneic/xenogeneic bone grafts in bone repairing
    Year: 2022
    Citations: 35
    Publication: ACS Biomaterials Science & Engineering
    Emoji: šŸ¦µšŸ”šŸ’”
  • Title: Exosomes and exosome-loaded scaffolds: characterization and application in modern regenerative medicine
    Year: 2023
    Citations: 26
    Publication: Tissue and Cell
    Emoji: šŸ§«šŸ”¬šŸŒ±
  • Title: A three dimensional in vivo model of breast cancer using a thermosensitive chitosanā€based hydrogel and 4 T1 cell line in Balb/c
    Year: 2021
    Citations: 25
    Publication: Journal of Biomedical Materials Research Part A
    Emoji: šŸŽ—ļøšŸ§¬šŸ”¬
  • Title: Evaluating the effects of vacuum on the microstructure and biocompatibility of bovine decellularized pericardium
    Year: 2021
    Citations: 24
    Publication: Journal of Tissue Engineering and Regenerative Medicine
    Emoji: šŸ§¬šŸ§ŖšŸ”¬
  • Title: Fabrication and characterization of Nanofibrous poly (L-lactic acid)/chitosan-based scaffold by liquidā€“liquid phase separation technique for nerve tissue engineering
    Year: 2021
    Citations: 21
    Publication: Molecular Biotechnology
    Emoji: šŸ§ šŸ§ŖšŸ§©
  • Title: Preparation and characterization of poly (ethylene oxide)/zinc oxide nanofibrous scaffold for chronic wound healing applications
    Year: 2020
    Citations: 21
    Publication: Polymers in Medicine
    Emoji: šŸ©¹šŸ§©šŸ”¬
  • Title: Anti-inflammatory and antioxidant effects of astaxanthin following spinal cord injury in a rat animal model
    Year: 2021
    Citations: 20
    Publication: Brain Research Bulletin
    Emoji: šŸ§ šŸ©¹šŸŒæ
  • Title: Exosome-loaded scaffolds for regenerative medicine in hard tissues
    Year: 2023
    Citations: 19
    Publication: Tissue and Cell
    Emoji: šŸ§¬šŸ”¬šŸ¦“

 

Ruipeng Jia | Tissue Engineering

Posted on by ScienceFather

Ā šŸ†Prof. Ruipeng Jia, šŸŽ‰ Congratulations on Your Best Researcher Award! šŸ†

  • Prof. Ruipeng Jia, Nanjing First Hospital, China- Leading Researcher in Tissue Engineering

Dr. Ruipeng Jia, šŸŽ‰ Heartiest Congratulations on being honored with the Best Researcher Award! šŸ† Your unwavering commitment to groundbreaking research in urology and tissue engineering has set a remarkable standard in our field. šŸŒŸ Your dedication and contributions are truly inspiring, and this recognition is well-deserved.

May this achievement be a testament to your passion for advancing medical knowledge and improving patient outcomes. šŸš€ Wishing you continued success on your journey of exploration and discovery. Keep shining and making a positive impact on the world of research! šŸ‘šŸ‘Øā€šŸ”¬

Professional Profiles:
Education Background
  • M.D., Shandong University, P.R. China – July 1999
    • Major: Urology
Working Experiences
  • Director of Urology, Nanjing First Hospital – June 2011 to September 2013
  • Head of Urology, Nanjing First Hospital – September 2013 to Present
Projects
  1. Technology development and clinical transformation of real-time navigation imaging system in minimally invasive surgery for benign prostatic hyperplasia
    • Jiangsu Provincial Key Research and Development Program – 2024.1 to 2026.12
  2. Mechanism of action of flexible graphene microarray gels compounded with Ad-SVF to promote bladder aging-mediated repair of UAB forced urinary muscle (92049111)
    • Natural Science Foundation of China – 2020.01 to 2022.12
  3. Mechanism of action of ad-SVF/ECM gel complex in repairing renal ischemia-reperfusion injury (BE2017615)
    • Natural Science Foundation of China – 2018.08 to 2020.12
Social Services

Ruipeng Jia is actively involved in various medical associations, holding leadership positions and contributing to committees in urology, male science, prostate health management, rehabilitation, sexology, immunology, and more.

This profile showcases a well-rounded professional with a strong academic background, significant research contributions, and active engagement in the medical community.

Research Focus

Ruipeng Jia’s primary research focus lies in urology, with a particular emphasis on the following areas:

  • Bladder Tissue Engineering: Developing artificial scaffolds and utilizing adipose-derived mesenchymal stem cells for bladder tissue engineering.
  • Renal Cell Carcinoma: Molecular typing and prognosis assessment using MicrorNa-based approaches.
  • Prostate Cancer: Investigating the role of Prostate-specific membrane antigen in cancer progression and the synthesis of arginine and proline.
  • Stromal Vascular Fraction (SVF): Utilizing SVF in therapeutic applications for conditions like underactive bladder and testicular injury.
  • Extracellular Vesicles: Studying the therapeutic potential of extracellular vesicles derived from various sources.
Professional Journey

Ruipeng Jia has held key positions at Nanjing First Hospital, including Director and Head of the Urology Department. His career trajectory has seen a progression from clinical roles to leadership positions. Additionally, he has actively participated in multiple research projects, contributing significantly to the field of urology.

Honors & Awards
  • Jiangsu Province New Technology Introduction Award (2019):
    • For work on MicrorNa-based Molecular Typing and Prognosis Assessment of Renal Cell Carcinoma.
  • Jiangsu Province New Technology Introduction Award (2013):
    • Recognized for the Application of inducible Prostaglandin synthetase mPGES1/COX2 in Hormone Independent Prediction and Treatment of prostate cancer.
  • Jiangsu Province New Technology Introduction Award (2016):
    • Acknowledged for MicrorNa-based Molecular Typing and Prognosis Assessment of Renal Cell Carcinoma.
Publications & Contributions

Ruipeng Jia has made significant contributions to the scientific community through a series of impactful publications. Some notable contributions include:

  • Publications (Selected)
    1. Negatively charged bladder acellular matrix loaded with positively charged adipose-derived mesenchymal stem cell-derived small extracellular vesicles for bladder tissue engineering. – J Control Release. 2023 Nov 7.
    2. Construction of tissue-engineered bladders using an artificial acellular nanocomposite scaffold loaded with stromal vascular fraction secretome. – Acta Biomater. 2023 Sep 1.
    3. Exosomal AP000439.2 from clear cell renal cell carcinoma induces M2 macrophage polarization to promote tumor progression through activation of STAT3. – Cell Commun Signal. 2022 Sep 24.
    4. Sig1R activates extracellular matrix-induced bladder cancer cell proliferation and angiogenesis by combining Ī²-integrin. – Aging (Albany NY). 2023 May 16.
    5. Therapeutic effect of adipose stromal vascular fraction spheroids for partial bladder outlet obstruction induced underactive bladder. – Stem Cell Res Ther. 2022 Feb 9.
Research Timeline
  1. 2024 – 2026:
    • Leading a project on the development and clinical transformation of a real-time navigation imaging system for minimally invasive surgery in benign prostatic hyperplasia.
  2. 2020 – 2022:
    • Investigating the mechanism of action of flexible graphene microarray gels for bladder aging-mediated repair.
    • Studying the mechanism of action of ad-SVF/ECM gel complex in repairing renal ischemia-reperfusion injury.
  3. 2019:
    • Awarded for the protective effects of uncultured adipose-derived stromal vascular fraction on testicular injury induced by torsion-detorsion in rats.
  4. 2018 – 2020:
    • Researching the mechanism of action of ad-SVF/ECM gel complex in repairing renal ischemia-reperfusion injury.
  5. 2016:
    • Recognized for MicrorNa-based Molecular Typing and Prognosis Assessment of Renal Cell Carcinoma.
  6. 2013:
    • Awarded for the application of inducible Prostaglandin synthetase mPGES1/COX2 in hormone-independent prediction and treatment of prostate cancer.
  7. 2011 – 2013:
    • Served as Director and subsequently Head of Urology at Nanjing First Hospital.

Ruipeng Jia’s research journey is characterized by a diverse range of projects, active involvement in clinical and leadership roles, and a consistent dedication to advancing knowledge in urology.